Document Detail

Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
MedLine Citation:
PMID:  18271940     Owner:  NLM     Status:  MEDLINE    
Disturbance of the normal functions of wild-type RUNX1 resulting from chromosomal translocations or gene mutations is one of the major molecular mechanisms in human leukemogenesis. RUNX1-related chimeras generated by the chromosomal translocations repress transcriptional activity of wild-type RUNX1 by recruiting the co-repressor/histone deacetylase complex. Thus, histone deacetylase inhibitors are expected to restore normal functions of wild-type RUNX1 and thereby affect the growth and differentiation ability of leukemic cells expressing the chimera. We investigated the in vitro effects of histone deacetylase inhibitors, trichostatin A and valproic acid, on human leukemic cell lines such as SKNO-1 and Kasumi-1 expressing RUNX1/ETO, Reh expressing TEL/RUNX1 and SKH-1 co-expressing RUNX1/EVI1 and BCR/ABL. We also employed K562 cells expressing BCR/ABL without such a chimera as a control. Treatment with each inhibitor increased acetylated histone 4 in all of these cell lines. Interestingly, proliferation of SKNO-1, Kasumi-1, SKH-1 and Reh cells was significantly suppressed after 3-day culture with trichostatin A or valproic acid, when compared to that of K562 cells. We observed cell cycle arrest and apoptotic induction in the RUNX1 chimera-expressing cells by the propidium iodide staining. Up- and downregulation of cell cycle regulator genes appeared to be the molecular basis for the former, and activation of both extrinsic and intrinsic apoptotic caspases for the latter. We propose histone deacetylase inhibitors to be an attractive choice in the molecular targeting therapy of RUNX1-related leukemia.
Ko Sasaki; Tetsuya Yamagata; Kinuko Mitani
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer science     Volume:  99     ISSN:  1349-7006     ISO Abbreviation:  Cancer Sci.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-14     Completed Date:  2008-04-22     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  101168776     Medline TA:  Cancer Sci     Country:  England    
Other Details:
Languages:  eng     Pagination:  414-22     Citation Subset:  IM    
Department of Hematology, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*
Apoptosis / physiology*
Cell Cycle
Cell Line, Tumor
Cell Proliferation
Core Binding Factor Alpha 2 Subunit / genetics*,  metabolism
Enzyme Inhibitors / pharmacology*
Histone Deacetylase Inhibitors*
Histone Deacetylases / metabolism
Hydroxamic Acids / pharmacology*
K562 Cells
Leukemia / genetics*,  metabolism
Mutant Chimeric Proteins / metabolism*
Valproic Acid / pharmacology*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Core Binding Factor Alpha 2 Subunit; 0/Enzyme Inhibitors; 0/Histone Deacetylase Inhibitors; 0/Hydroxamic Acids; 0/Mutant Chimeric Proteins; 0/RUNX1 protein, human; 58880-19-6/trichostatin A; 99-66-1/Valproic Acid; EC Deacetylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected wi...
Next Document:  Novel application of multicellular layers culture for in situ evaluation of cytotoxicity and penetra...